ERGIC3

Across TCGA pan-cancer cohorts, ERGIC3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ERGIC3 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ERGIC3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ERGIC3 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where ERGIC3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.629	1.000	.002	45	view →
PDAC	DFS	Quartile	All	0.247	0.634	<.001	14	view →
HNSC	DFS	Tertile	III,IV	0.887	1.000	.014	6	view →
LUAD	OS	Median	III,IV	0.776	0.243	.008	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ERGIC3–CCRCC (OS)

Open the CCRCC breakdown →